LGVN4:05 PMLongeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Prioritieslongeveron.com
LGVN4:05 PMLongeveron Announces 2026 First Quarter Financial Results and Provides Business Updatelongeveron.com
LGVN9:10 AMLongeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)longeveron.com
LGVN4:05 PMLongeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)longeveron.com
LGVN4:15 PMLongeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026longeveron.com
LGVN9:15 AMLongeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)longeveron.com
LGVN4:05 PMLongeveron Announces 2025 Full Year Financial Results and Provides Business Updatelongeveron.com
LGVN9:00 AMLongeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026longeveron.com